AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $756.25M
• Dividend Yield: N/A
• Average Volume (3M): 641.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 387.20%
• EPS Growth: 21.00%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 29,380,495
• 10 Day Avg. Volume: 522,707
• 30 Day Avg. Volume: 641,762
• PEG Ratio: -0.06
• Price to Book (P/B): 3.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.80
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 2.82
• Enterprise Value/Gross Profit: 7.42
• Enterprise Value/Ebitda: -1.85
• 1Y Price Target: $47.63
• Price Target Upside: 81.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 55 Neutral
• Price Target: $27.00 ▲(3.05%Upside)

AnaptysBio's overall stock score reflects strong technical momentum and positive corporate developments countered by financial challenges. The positive trial results offer a potential growth catalyst, while the unprofitability and valuation concerns limit the score.

Positive Factors

Clinical Trials

Positive results from Ph 2 RENOIR evaluating PD-1 agonist rosnilimab for rheumatoid arthritis included efficacy comparable to JAK inhibitors, deepening of response, and no safety signals relative to placebo.

Efficacy and Safety

ANAB's rosnilimab demonstrated strong efficacy and durability across both biologic-naïve and experienced populations in rheumatoid arthritis.

Market Performance

Shares are up 76% year-to-date, as investors see ANAB's Jemperli royalty value as a floor for the stock and incremental data for rosnilimab continues to demonstrate a differentiated efficacy and safety profile in RA.

Negative Factors

Competition Concerns

Disappointing UC results for competitor JNJ’s PD-1 agonist JNJ-67484703 raise questions about rosnilimab’s Ph2b UC readout, although JNJ's data in RA appears weaker cross-trial relative to rosnilimab.

Uncertainty in UC Trials

Despite the potential for rosnilimab, questions remain regarding the Ph2b UC readout, especially in light of competitive landscape and JNJ's struggles in this area.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company that specializes in the development of novel antibody therapies. Operating in the biopharmaceutical sector, AnaptysBio focuses primarily on the discovery and development of first-in-class immunology therapeutic antibodies aimed at treating inflammatory diseases. The company leverages its proprietary somatic hypermutation (SHM) antibody platform to generate high-affinity therapeutic antibodies against various biological targets.

How the Company Makes Money

AnaptysBio primarily generates revenue through strategic collaborations and partnerships with larger pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and potential royalties on product sales resulting from the development and commercialization of antibody therapies. Additionally, the company may also earn revenue through licensing agreements of its proprietary technologies to other entities in the pharmaceutical industry. AnaptysBio's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the success of its collaboration agreements.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio is showing strong revenue growth but continues to face significant profitability and cash flow challenges. The company remains unprofitable, with negative margins and returns. The balance sheet shows moderate leverage, but equity levels are low. Overall, the company needs to focus on enhancing profitability and cash flow to strengthen its financial position.

Income Statement

AnaptysBio has experienced substantial revenue growth from $10.3M in 2022 to $111.9M TTM, indicating a strong upward trajectory. However, the company continues to operate at a loss, with a negative net profit margin of -125.7% and a negative EBIT margin of -89.7% TTM. This suggests significant profitability challenges despite revenue growth.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 0.46 TTM, indicating moderate leverage. The equity ratio stands at 8.1% TTM, reflecting a relatively low proportion of equity financing. The negative ROE of -413.2% TTM points to ongoing profitability issues impacting shareholder returns.

Cash Flow

AnaptysBio's free cash flow improved slightly from -$135.7M in 2024 to -$102.2M TTM, but remains negative, indicating cash flow challenges. The operating cash flow to net income ratio of 0.72 TTM shows that cash losses are closely aligned with accounting losses, highlighting limited cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	111.87M	91.28M	17.16M	10.29M	63.17M	75.00M
Gross Profit	110.68M	88.88M	14.78M	7.95M	-35.32M	-5.03M
EBITDA	-83.27M	-92.74M	-143.16M	-105.26M	-55.71M	-19.37M
Net Income	-140.62M	-145.23M	-163.62M	-128.72M	-57.19M	-19.92M
Balance Sheet
Total Assets	422.05M	483.83M	452.39M	610.38M	643.07M	416.55M
Cash, Cash Equivalents and Short-Term Investments	339.94M	385.37M	390.90M	441.24M	548.10M	393.65M
Total Debt	15.57M	16.04M	17.81M	19.45M	20.95M	342.00K
Total Liabilities	388.03M	412.97M	364.29M	348.28M	286.64M	19.82M
Stockholders Equity	34.02M	70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow
Free Cash Flow	-102.21M	-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
Operating Cash Flow	-101.84M	-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
Investing Cash Flow	41.63M	95.40M	144.75M	-394.85M	38.84M	94.47M
Financing Cash Flow	105.16M	127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 26.2 is above the 20-day moving average (MA) of 23.72, above the 50-day MA of 22.23, and above the 200-day MA of 21.23, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 69.08 is Neutral, neither overbought nor oversold. The STOCH value of 92.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	66 Neutral	$706.69M	―	-6.33%	―	23.92%	-27.69%
Sector *	65 Neutral	€6.58B	20.31	-1.30%	2.21%	-0.16%	-45.39%
IMTX	58 Neutral	$717.15M	53.85	-4.52%	―	92.31%	78.17%
ANAB	55 Neutral	$756.25M	―	-343.83%	―	387.20%	21.00%
TRVI	55 Neutral	$763.72M	―	-55.12%	―	―	-60.26%
VALN	47 Neutral	$506.97M	―	-43.77%	―	20.38%	-194.93%
SVRA	46 Neutral	$397.52M	―	-75.77%	―	―	-44.25%

AnaptysBio Corporate Events

AnaptysBio Holds 2025 Annual Stockholders Meeting

On June 17, 2025, AnaptysBio, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were adopted. These included the election of three Class II directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the approval of amendments to the company’s 2017 Equity Incentive Plan. The meeting also featured non-binding advisory votes on executive compensation and the frequency of future advisory votes concerning executive compensation. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

AnaptysBio Reports Positive Phase 2b Trial Results

On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis. The trial demonstrated that rosnilimab achieved JAK-like efficacy with significant improvements in disease activity and remission rates, maintaining durable responses for at least two months off drug. The findings suggest rosnilimab’s potential for extended dosing intervals and its promising impact in the $20 billion U.S. RA market.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.